Summary
LONDON and NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) — OKYO Pharma Limited (Nasdaq:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, t
Source: GlobeNewswire
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
